NxStage Kidney Care Hosts Grand Opening Celebration Of New State-Of-The-Art Dialysis Center In St. Louis

Tuesday October 15, 2013


NxStage Kidney Care will be hosting a Grand Opening celebration and ribbon-cutting reception for its new state-of-the-art dialysis center in Des Peres, MO. The Grand Opening, which is open to the public, will include a ribbon cutting reception, tours of the 6,300 sq. ft. facility, and an opportunity to meet the center staff as well as recording artist and former NxStage&reg System One™ patient, David RUSH.

The center staff includes Dr. Pablo Dayer, MD, Medical Director of NxStage Kidney Care Center St. Louis. He is a board certified nephrologist, specializing in kidney disease and hypertension, at Medical Specialists of St. Luke’s Hospital. He was chief resident in internal medicine at St. Luke’s and chief fellow in nephrology at St. Louis University Hospital.


Tuesday, October 22, 2013 from 2:00-6:00 pm CDT
2:00 pm — Ribbon Cutting
2:15- 6:00 pm— Reception/Tours/ Special Guest David RUSH


NxStage Kidney Care St. Louis
1076 Old Des Peres Road
Des Peres, MO 63131

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

About NxStage Kidney Care

NxStage Kidney Care Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), is innovating a dialysis care model that is intended to support and encourage patient centered care by providing enhanced access to the life-changing benefits of home therapy as well as flexible in-center options. By leveraging NxStage’s home leadership and the innovative technology of its System One™, NxStage Kidney Care is committed to helping patients take control of their dialysis and to allowing physicians the flexibility to prescribe what is truly best for their patients. For more information, please visit www.nxstagekidneycare.com or call 866-694-2707 to learn more about the NxStage Kidney Care.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company’s website at www.nxstage.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.
VP, Investor Relations

/PRNewswire — Oct. 15, 2013/

SOURCE NxStage Kidney Care Inc.

News Provided by Acquire Media